The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study to evaluate the efficacy and safety of rilotumumab and bevacizumab (BEV) in subjects with recurrent malignant glioma (MG).
Mary Lou Affronti
No relevant relationships to disclose
Annick Desjardins
Consultant or Advisory Role - Roche/Genentech
Henry S. Friedman
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech
Katherine B. Peters
No relevant relationships to disclose
James E Herndon II
No relevant relationships to disclose
Frances McSherry
No relevant relationships to disclose
Eric S Lipp
No relevant relationships to disclose
Alise Brickhouse
No relevant relationships to disclose
Woody C Massey
No relevant relationships to disclose
Elizabeth Miller
No relevant relationships to disclose
Sprague Cheshire
No relevant relationships to disclose
Christina Cone
No relevant relationships to disclose
Katherine H Kalinowski
No relevant relationships to disclose
Jung-Young Kim
No relevant relationships to disclose
Harry H Lay
No relevant relationships to disclose
Victoria Poillucci
No relevant relationships to disclose
Cindy Southerland
No relevant relationships to disclose
Jill Tetterton
No relevant relationships to disclose
James J Vredenburgh
Consultant or Advisory Role - Roche/Genentech
Honoraria - Roche/Genentech